Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Annovis Bio ( ($ANVS) ) has issued an announcement. On June 17, 2026, Annovis Bio, Inc. held its 2026 Annual Meeting of Stockholders virtually, wit...

Annovis Bio Shareholders Approve Governance and Compensation Changes

Citi analyst Graham Parry maintained a Buy rating on Novartis AG yesterday. The company’s shares closed yesterday at CHF122.08. According to TipRan...

Citi Remains a Buy on Novartis AG (NOVN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY), Insulet (PODD) and Novartis ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novartis, with a price target of CHF140.00. Jain...

Bank of America Securities Remains a Buy on Novartis (NVS)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG today and set a price target of CHF135.00. Papadakis covers the Hea...

Deutsche Bank  Reaffirms Their Buy Rating on Novartis AG (NOVN)

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG, with a price target of CHF116.00. According to TipRank...

Novartis AG (NOVN) Receives a Hold from UBS

Barclays analyst James Gordon CFA maintained a Hold rating on Novartis AG today and set a price target of CHF120.00. Gordon CFA covers the Healthca...

Barclays Keeps Their Hold Rating on Novartis AG (NOVN)

Argus Research analyst Jasper Hellweg maintained a Buy rating on Novartis yesterday and set a price target of $160.00. Hellweg covers the Healthcar...

Argus Research Reaffirms Their Buy Rating on Novartis (NVS)

Cineverse ( ($CNVS) ) has issued an update. On April 15, 2026, Cineverse Corp. announced that Chief Financial Officer Mark Lindsey would leave his ...

Cineverse Announces CFO Departure and Transition Consulting Role

Deutsche Bank  Keeps Their Buy Rating on Novartis AG (NOVN)

Envista Holdings ( ($NVST) ) has shared an announcement. Envista Holdings Corporation reported the results of its 2026 Annual Meeting of Stockholde...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$147.08	-2.52%	1.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$147.08	-2.5%	1.87M
3
4
5
6

NVS

NVS

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel